Relevant bibliographies by topics / Drug problems / Journal articles
To see the other types of publications on this topic, follow the link: Drug problems.

Journal articles on the topic 'Drug problems'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug problems.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Plant, Martin A. "Drugs and drug problems." Midwifery 1, no. 3 (September 1985): 133–34. http://dx.doi.org/10.1016/s0266-6138(85)80030-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Burger, Candice. "Treat Drug Problems With Drugs?" Contemporary Psychology: A Journal of Reviews 30, no. 7 (July 1985): 556. http://dx.doi.org/10.1037/023917.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Randall, Helen. "Drug promotional problems." Medical Journal of Australia 150, no. 8 (April 1989): 463. http://dx.doi.org/10.5694/j.1326-5377.1989.tb136573.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gerstein, Dean R., and Lawrence S. Lewin. "Treating Drug Problems." New England Journal of Medicine 323, no. 12 (September 20, 1990): 844–48. http://dx.doi.org/10.1056/nejm199009203231230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fai-kam, Kanyanat, Yatima Nuchdang, Yupawarat Kentekrom, Prayuth Chusorn, and Pornpimon Chusorn. "Preventing and solving the narcotic drug problems in Thailand." New Trends and Issues Proceedings on Humanities and Social Sciences 2, no. 2 (January 12, 2016): 37–41. http://dx.doi.org/10.18844/gjhss.v2i2.413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gonçalves, Angelica, Ana Arciprete, Tereza Barroso, and Sandra Pillon. "Cross-cultural adaptation and validation of the Drug and Drug Problems Perceptions Questionnaire for Brazil." Revista de Enfermagem Referência IV Série, no. 19 (December 26, 2018): 11–20. http://dx.doi.org/10.12707/riv18014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pennings, Pleuni S. "HIV drug resistance: problems and perspectives." Infectious Disease Reports 5, no. 1S (June 6, 2013): 5. http://dx.doi.org/10.4081/idr.2013.s1.e5.

Full text
Abstract:
Access to combination antiretroviral treatment (ART) has improved greatly over recent years. At the end of 2011, more than eight million HIV-infected people were receiving ART in low-income and middle-income countries. ART generally works well in keeping the virus suppressed and the patient healthy. However, treatment only works as long as the virus is not resistant against the drugs used. In the last decades, HIV treatments have become better and better at slowing down the evolution of drug resistance, so that some patients are treated for many years without having any resistance problems. However, for some patients, especially in low-income countries, drug resistance is still a serious threat to their health. This essay will review what is known about transmitted and acquired drug resistance, multi-class drug resistance, resistance to newer drugs, resistance due to treatment for the prevention of mother-to-child transmission, the role of minority variants (low-frequency drug-resistance mutations), and resistance due to pre-exposure prophylaxis.
APA, Harvard, Vancouver, ISO, and other styles
8

Garcia, Maria Lúcia Teixeira. "Russia and Intolerance towards Drug Problems." Journal of Sociological Research 5, no. 1 (May 19, 2014): 113. http://dx.doi.org/10.5296/jsr.v5i1.5648.

Full text
Abstract:
The aim of this article is to examine the problem of drug use in Russia by analysing the direction taken by the drug policies in that country. We conducted an Internet-based literature search using two keywords in English: Russia and drug policy. We began reading the materials identified in the search and organising data. The other sources we used included the websites for the World Health Organization and the Federal Drug Control Service of the Russian Federation. The estimated number of people who use illegal drugs in Russia is five million, and of these, 1.7 million are opiate users. In 2012, approximately 2.5 million Russians were drug-dependent[1], and 90% of them used heroin from Afghanistan. With a population of 143 million people, Russia consumes 70 tons of Afghan heroin every year – more than one-fifth of the drug consumed globally – according to the United Nations Office on Drugs and Crime. Russian drug policy thus calls the world’s attention to what we should not do: focus public policy on actions known to be ineffective for responding to drug use problems.[1] CNPq and Fapes researcher. Research study (no. 485937/2012-3) funded by CNPq – Brazilian National Council for Scientific and Technological Development. Member of Fênix group2 The number of heroin users in countries in Western Europe such as Germany or the United Kingdom is significantly lower – up to 150,000 and 300,000, respectively, according to several estimates.
APA, Harvard, Vancouver, ISO, and other styles
9

Bor, Andrea, Mária Matuz, Péter Doró, Réka Viola, and Gyöngyvér Soós. "Drug-related problems in the elderly." Orvosi Hetilap 153, no. 49 (December 2012): 1926–36. http://dx.doi.org/10.1556/oh.2012.29500.

Full text
Abstract:
The aging population in developed countries is a growing problem nowadays. The burden on healthcare is particularly high, since the prevalence of the diseases, especially chronic diseases increases with age. Prevalence of polypharmacy is common among elderly patients. While comorbidities require usage of several active agents with evidence based indication, polypharmacy increases the likelihood of interactions and adverse drug reactions, reduces patient compliance, affects quality of life and puts a significant financial burden on the patient and society. In order to reduce drug-related problems among the elderly, different lists of potentially inappropriate drugs and doses were created. One of the earliest known lists is the “Beers criteria”. The use of listed drugs is risky and not recommended for elderly patients. Following foreign examples, a list was compiled and adapted to the Hungarian drug spectrum based on the main concerns and alternative therapeutic suggestions. Orv. Hetil., 2012, 153, 1926–1936.
APA, Harvard, Vancouver, ISO, and other styles
10

Hanlon, Joseph T. "Drug-related problems updates." American Journal of Geriatric Pharmacotherapy 2, no. 1 (March 2004): 88–90. http://dx.doi.org/10.1016/s1543-5946(04)90011-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

McDonough, Randy P. "Finding Drug Therapy Problems." Journal of the American Pharmaceutical Association (1996) 39, no. 4 (April 1999): 568–70. http://dx.doi.org/10.1016/s1086-5802(16)30479-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Wooten, James M. "Drug-Induced Sexual Problems." Southern Medical Journal 101, no. 11 (November 2008): 1092–93. http://dx.doi.org/10.1097/smj.0b013e318182ee78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Chen, Zhonglin, and Kaicheng Huang. "Drug Problems in China." International Journal of Offender Therapy and Comparative Criminology 51, no. 1 (February 2007): 98–109. http://dx.doi.org/10.1177/0306624x06295717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Knight, John R., Luis T. Sanchez, Lon Sherritt, Linda R. Bresnahan, Jennifer M. Silveria, and John A. Fromson. "Monitoring Physician Drug Problems." Journal of Addictive Diseases 21, no. 4 (September 20, 2002): 27–36. http://dx.doi.org/10.1300/j069v21n04_03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Mitka, Mike. "Drug Shortage Problems Continue." JAMA 311, no. 14 (April 9, 2014): 1389. http://dx.doi.org/10.1001/jama.2014.3007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

della Valle, Francesco. "Italian drug problems clarified." Nature 365, no. 6443 (September 1993): 202. http://dx.doi.org/10.1038/365202a0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Dewulf, Pieter, Michiel Stock, and Bernard De Baets. "Cold-Start Problems in Data-Driven Prediction of Drug–Drug Interaction Effects." Pharmaceuticals 14, no. 5 (May 2, 2021): 429. http://dx.doi.org/10.3390/ph14050429.

Full text
Abstract:
Combining drugs, a phenomenon often referred to as polypharmacy, can induce additional adverse effects. The identification of adverse combinations is a key task in pharmacovigilance. In this context, in silico approaches based on machine learning are promising as they can learn from a limited number of combinations to predict for all. In this work, we identify various subtasks in predicting effects caused by drug–drug interaction. Predicting drug–drug interaction effects for drugs that already exist is very different from predicting outcomes for newly developed drugs, commonly called a cold-start problem. We propose suitable validation schemes for the different subtasks that emerge. These validation schemes are critical to correctly assess the performance. We develop a new model that obtains AUC-ROC =0.843 for the hardest cold-start task up to AUC-ROC =0.957 for the easiest one on the benchmark dataset of Zitnik et al. Finally, we illustrate how our predictions can be used to improve post-market surveillance systems or detect drug–drug interaction effects earlier during drug development.
APA, Harvard, Vancouver, ISO, and other styles
18

Akutsu, Mamoru. "Current Status of Drug Problems and Drug Analysis." YAKUGAKU ZASSHI 139, no. 5 (May 1, 2019): 693–97. http://dx.doi.org/10.1248/yakushi.18-00166-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Kr??henb??hl-Melcher, Anita, Raymond Schlienger, Markus Lampert, Manuel Haschke, J??rgen Drewe, and Stephan Kr??henb??hl. "Drug-Related Problems in Hospitals." Drug Safety 30, no. 5 (2007): 379–407. http://dx.doi.org/10.2165/00002018-200730050-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

HENRY, J. A. "SPECIFIC PROBLEMS OF DRUG INTOXICATION." British Journal of Anaesthesia 58, no. 2 (February 1986): 223–33. http://dx.doi.org/10.1093/bja/58.2.223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Johns, Andrew. "Private treatment for drug problems." British Journal of Addiction 86, no. 10 (October 1991): 1355–56. http://dx.doi.org/10.1111/j.1360-0443.1991.tb01711.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

&NA;. "Problems in Pediatric Drug Therapy." American Journal of Nursing 96, no. 3 (March 1996): 56. http://dx.doi.org/10.1097/00000446-199603000-00034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Drayer, Dennis E. "Problems in Therapeutic Drug Monitoring." Therapeutic Drug Monitoring 10, no. 1 (March 1988): 1–7. http://dx.doi.org/10.1097/00007691-198801000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Barre, Jérôme, Frédéric Didey, François Delion, and Jean-Paul Tillement. "Problems in Therapeutic Drug Monitoring." Therapeutic Drug Monitoring 10, no. 2 (June 1988): 133–43. http://dx.doi.org/10.1097/00007691-198802000-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Drayer, Dennis E. "Problems in Therapeutic Drug Monitoring." Therapeutic Drug Monitoring 10, no. 1 (1988): 1–7. http://dx.doi.org/10.1097/00007691-198810010-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Pagliaro, Louis A., Ann M. Pagliaro, and Jo Ann Jackson. "Problems in Pediatric Drug Therapy." Therapeutic Drug Monitoring 11, no. 1 (January 1989): 118. http://dx.doi.org/10.1097/00007691-198901000-00030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Mulligan-Smith, Deborah. "Problems in Pediatric Drug Therapy." Pediatric Emergency Care 12, no. 5 (October 1996): 387. http://dx.doi.org/10.1097/00006565-199610000-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

McGovern, Thomas F. "Alcohol and Other Drug Problems." Alcoholism Treatment Quarterly 23, no. 4 (September 2005): 1–2. http://dx.doi.org/10.1300/j020v23n04_01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

McGovern, Thomas F. "Alcohol and Other Drug Problems." Alcoholism Treatment Quarterly 24, no. 3 (October 17, 2006): 1–2. http://dx.doi.org/10.1300/j020v24n03_01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Farrugia, Adrian. "Third Contemporary Drug Problems Conference." Contemporary Drug Problems 43, no. 1 (December 31, 2015): 4–5. http://dx.doi.org/10.1177/0091450915619077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Lancaster, Kari. "Fourth Contemporary Drug Problems Conference." Contemporary Drug Problems 44, no. 4 (October 27, 2017): 375–76. http://dx.doi.org/10.1177/0091450917739449.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Barinaga, Marcia. "Problems with anti-clotting drug." Nature 335, no. 6193 (October 1988): 751. http://dx.doi.org/10.1038/335751a0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Bart, Gavin. "Emerging drug problems in Asia." Journal of Food and Drug Analysis 21, no. 4 (December 2013): S19—S20. http://dx.doi.org/10.1016/j.jfda.2013.09.025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Chaves-Carballo, Enrique. "Problems in pediatric drug therapy." Pediatric Neurology 13, no. 2 (September 1995): 181. http://dx.doi.org/10.1016/0887-8994(95)90028-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Gal, Peter. "Therapeutic Drug Monitoring in Neonates: Problems and Issues." Drug Intelligence & Clinical Pharmacy 22, no. 4 (April 1988): 317–23. http://dx.doi.org/10.1177/106002808802200411.

Full text
Abstract:
Therapeutic drug monitoring has been applied in several patient populations to promote safer, more effective use of drugs. The development of therapeutic ranges allows clinicians to aim for a plasma drug concentration that is usually safe and effective, and calculation of specific pharmacokinetic parameters allows selection of doses that will achieve the desired plasma concentration. This concept certainly holds true in the intensive care nursery; however, the intensity of monitoring in this setting provides opportunities for far broader application of the information obtained from drug concentration monitoring. This review provides an overview of the complexity of and potential applications for therapeutic drug monitoring in neonates based on literature and clinical experience.
APA, Harvard, Vancouver, ISO, and other styles
36

Vasil’eva, I. A., A. G. Samoilova, A. E. Ergeshov, T. R. Bagdasaryan, and L. N. Chernousova. "CHEMOTHERAPY OF TUBERCULOSIS: PROBLEMS AND PERSPECTIVES." Annals of the Russian academy of medical sciences 67, no. 11 (November 10, 2012): 9–14. http://dx.doi.org/10.15690/vramn.v67i11.465.

Full text
Abstract:
Challenges of tuberculosis chemotherapy under conditions of high drug resistant (DR) tuberculosis burden are discussed. Ultimate results of treatment by standard regimens of 1658 patients with new tuberculosis cases and relapses were analyzed. Favorable ultimate results were observed among both patients with new tuberculosis cases and relapses having drugs sensitivity. Efficacy of tuberculosis treatment by standard regimens of chemotherapy is decreasing as a result of DR amplification. Risk factors of unfavorable ultimate result among pulmonary tuberculosis patients are primary resistance to isoniazid (OR =2,1) and multiple drug resistance of M. tuberculosis (OR =8,0). Earlier onset of treatment and correct individual therapy with second line drugs as a result of rapid methods of DR tuberculosis diagnostics are those approaches which provide the best therapeutic effect among multiple drug resistant tuberculosis patients both in culture conversion (97,7%) and cavity closure rate (82,7%).
APA, Harvard, Vancouver, ISO, and other styles
37

Muhammad Arfat Yameen, Mubashra Tafseer, Warda Khan, Sanaa Anjum, Raza-E-Mustafa, and Ossam Chohan. "Trends in Prescribing Patterns and Drug Related Problems of Kidney Disease Patients." Journal of the Pakistan Medical Association 71, no. 11 (November 29, 2021): 2629–36. http://dx.doi.org/10.47391/jpma.01816.

Full text
Abstract:
Objective: The aim of the study was the evaluation of drug-related problems, including drug-drug interactions, dose error, use of nephrotoxic drugs and polypharmacy with special emphasis on kidney disease patients. Methods: Descriptive cross-sectional study from January to April 2019 was carried out in nephrology ward of Ayub teaching hospital, Abbottabad, Pakistan to review patient’s medication orders for evaluation of drug-related problems. Doses of medicine and drug-drug interactions were evaluated by comparing it with standard protocols given in BNF and Lexicomp software. Prescriptions were also evaluated for polypharmacy and use of nephrotoxic drugs. Results: Out of 131 patients, majority were males 72 (55%). Drug-drug interactions were found in 69 (52.7%) patients among which the highest percentage was of the moderate drug-drug interaction (48.1%) followed by major and minor drug-drug interaction (29.8% and 20.6% respectively). Incidence of polypharmacy (51.9%) and use of nephrotoxic drug (77%) was high while dose error was low up to 10.7%. All the drug-related problems were present with a high percentage in patients with CKD as compare to other kidney diseases. There was significant association of CKD stages with DDIs, polypharmacy, dose error and prescribing drugs. There was significant positive correlation among DDIs-polypharmacy and prescribing drugs was noted in the study. Conclusion: The higher incidence of drug-related problems in our study setting reflects irrational prescribing trends and deficiency of professional staff dealing kidney disease patients. Key Words: kidney disease, drug-drug interactions, polypharmacy, nephrotoxic drugs, dose error. Continuous...
APA, Harvard, Vancouver, ISO, and other styles
38

Gassman, Ruth A., and Constance Weisner. "Community Providers' Views of Alcohol Problems and Drug Problems." Journal of Social Work Practice in the Addictions 5, no. 4 (December 2005): 101–15. http://dx.doi.org/10.1300/j160v05n04_07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Cohen, Lauren, Umit G. Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 1, 2021): 67–82. http://dx.doi.org/10.1257/aeri.20200086.

Full text
Abstract:
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly more adverse effects, including more hospitalizations, life-threatening incidents, and deaths—particularly, drugs most rushed through the approval process. These patterns are consistent with a model in which regulators rush to meet internal production benchmarks associated with salient calendar periods: this “ desk-clearing” behavior results in more lax review, leading both to increased output and increased safety issues at particular—and predictable—periodicities over the year. (JEL D83, I11, L51, L65)
APA, Harvard, Vancouver, ISO, and other styles
40

Randhawa, Mohammad A., Hatem O. Qutub, Mastour S. Alghamdi, Raniah A. Al-Jaizani, Rayan Y. Mushtaq, and Mohammad J. Akbar. "Drug Related Problems at the Intensive Care Unit of a University Hospital in Saudi Arabia." Saudi Journal of Internal Medicine 5, no. 1 (June 30, 2015): 11–18. http://dx.doi.org/10.32790/sjim.2015.5.1.3.

Full text
Abstract:
Background: Medication errors can lead to mild or severe drug related problems. Drug related problems are sometimes unpredictable and can occur without medication errors. Awareness and identification of medication errors and drug related problems aids in adoption of measures to prevent and treat them. Objective: Present study aimed to find out prevalence of drug related problems reporting or occurring at Intensive Care Unit of King Fahd Hospital of the University, Alkhobar, Saudi Arabia. Methods: Scrutinizing written files of all patients reporting to Intensive Care Unit, from January to December 2012. Results: Out of 193 files reviewed, 33 patients (17.1%) had trivial to serious drug related problems, including 8 (4.1%) deaths. Drugs commonly involved in these problems were anticoagulants (Warfarin and heparin, alone or in combination with aspirin or clopidogrel; 8 cases, 24.2%), antiepileptic drugs (Carbamazepine and phenytoin; 6 cases, 18.2%), immune suppressants (Azathioprine and prednisolone; 4 cases, 12.1%), antibiotics (Ciprofloxacin, imipenum, tazocin and vancomycin; 4 cases, 12.1%) and drugs of abuse and dependence (Alcohol, benzodiazepines, cannabis and opioids; 4 cases, 12.1%). Amongst drug related problems detected, 6 cases (18.2%) were linked to drug interactions. Almost 60% of drug related problems found were preventable, including those due to overdose toxicity, non-compliance and drug-drug interactions. Conclusions: Mild to severe drug related problems occurred in intensive care unit of a university hospital and about half of them were preventable. It is hoped that the awareness and insight of drug related problems will help to improve patient care.
APA, Harvard, Vancouver, ISO, and other styles
41

Hanlon, Joseph T., Leslie A. Shimp, and Todd P. Semla. "Recent Advances in Geriatrics: Drug-Related Problems in the Elderly." Annals of Pharmacotherapy 34, no. 3 (March 2000): 360–65. http://dx.doi.org/10.1345/aph.19140.

Full text
Abstract:
OBJECTIVE: To review recent articles examining drug-related problems in the elderly and comment on their potential impact on geriatric pharmacy practice. DATA SOURCES: Six articles published in 1997 and 1998. DATA SYNTHESIS: One study estimated that the cost of drug-related morbidity and mortality with the services of consultant pharmacists was $4 billion, compared with $7.6 billion without the services of consultant pharmacists. A study of ambulatory elderly patients with polypharmacy documented that 35% reported experiencing at least one adverse drug event within the previous year. Another study of ambulatory elderly found that in those with discontinued medications, adverse drug withdrawal events were uncommon. Two studies, one from Canada and one from the US, describe the development, by consensus, of explicit criteria for defining and identifying inappropriate drug use in the elderly (i.e., drugs to avoid, drugs with dose limits, drug–drug and drug–disease interactions). Finally, a modified Delphi survey of an expert panel reached consensus on 18 potential risk factors for drug-related factors in long-term care facility residents. CONCLUSIONS: Drug-related problems are considerable for elderly patients. Data from published studies should provide some guidance for today's practitioners as well as direction regarding future research.
APA, Harvard, Vancouver, ISO, and other styles
42

Reimold, S. C. "Avoiding drug problems: The safety of drugs for supraventricular tachycardia." European Heart Journal 18, suppl C (May 2, 1997): 40–44. http://dx.doi.org/10.1093/eurheartj/18.suppl_c.40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Gabrič, Alen, Žiga Hodnik, and Stane Pajk. "Oxidation of Drugs during Drug Product Development: Problems and Solutions." Pharmaceutics 14, no. 2 (January 29, 2022): 325. http://dx.doi.org/10.3390/pharmaceutics14020325.

Full text
Abstract:
Oxidation is the second most common degradation pathway for pharmaceuticals, after hydrolysis. However, in contrast to hydrolysis, oxidation is mechanistically more complex and produces a wider range of degradation products; oxidation is thus harder to control. The propensity of a drug towards oxidation is established during forced degradation studies. However, a more realistic insight into degradation in the solid state can be achieved with accelerated studies of mixtures of drugs and excipients, as the excipients are the most common sources of impurities that have the potential to initiate oxidation of a solid drug product. Based on the results of these studies, critical parameters can be identified and appropriate measures can be taken to avoid the problems that oxidation poses to the quality of a drug product. This article reviews the most common types of oxidation mechanisms, possible sources of reactive oxygen species, and how to minimize the oxidation of a solid drug product based on a well-planned accelerated study.
APA, Harvard, Vancouver, ISO, and other styles
44

Shimp, Leslie A., Frank J. Ascione, Howard M. Glazer, and Beverly F. Atwood. "Potential Medication-Related Problems in Noninstitutionalized Elderly." Drug Intelligence & Clinical Pharmacy 19, no. 10 (October 1985): 766–72. http://dx.doi.org/10.1177/106002808501901024.

Full text
Abstract:
The extent of potential medication-related problems was examined using a thorough review of drug therapy for 53 elderly patients who averaged five chronic illnesses and who used a mean of 11 drugs. An average of 11 specific potential medication-related problems was identified for each patient. These problems fell into three broad categories: Drug toxicity, physician prescribing, and patient medication behaviors. The strongest predictor of the total number of potential problems was the number of prescription medications. The type of drug therapy review used in this study can help health professionals identify and prevent the types of medication-related problems occurring in multiple medication users.
APA, Harvard, Vancouver, ISO, and other styles
45

Di Mizio, Giulio, Gianmarco Marcianò, Caterina Palleria, Lucia Muraca, Vincenzo Rania, Roberta Roberti, Giuseppe Spaziano, et al. "Drug–Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications." International Journal of Environmental Research and Public Health 18, no. 24 (December 8, 2021): 12936. http://dx.doi.org/10.3390/ijerph182412936.

Full text
Abstract:
Peripheral vestibular disease can be treated with several approaches (e.g., maneuvers, surgery, or medical approach). Comorbidity is common in elderly patients, so polytherapy is used, but it can generate the development of drug–drug interactions (DDIs) that play a role in both adverse drug reactions and reduced adherence. For this reason, they need a complex kind of approach, considering all their individual characteristics. Physicians must be able to prescribe and deprescribe drugs based on a solid knowledge of pharmacokinetics, pharmacodynamics, and clinical indications. Moreover, full information is required to reach a real therapeutic alliance, to improve the safety of care and reduce possible malpractice claims related to drug–drug interactions. In this review, using PubMed, Embase, and Cochrane library, we searched articles published until 30 August 2021, and described both pharmacokinetic and pharmacodynamic DDIs in patients with vestibular disorders, focusing the interest on their clinical implications and on risk management strategies.
APA, Harvard, Vancouver, ISO, and other styles
46

Shestakov, V., S. Polyakov, L. Persanova, T. Andreevicheva, M. Veretennikova, A. Ulianov, V. Skupchenko, et al. "Medicines for pediatric use: problems and research." Novejshie zarubezhnye i otechestvennye lekarstvennye preparaty: farmakoterapija, farmakodinamika, farmakokinetika (Newest Foreign and Domestic Preparations: Pharmacotherapy, Pharmacodynamics, Pharmacokinetics), no. 2 (April 1, 2020): 55–61. http://dx.doi.org/10.33920/med-06-2002-04.

Full text
Abstract:
The prescription of drugs in pediatrics is currently associated with problems. Therapists are often faced with "off-label drug use", the lack of drugs in appropriate doses for children and, the need to develop appropriate dosage forms.
APA, Harvard, Vancouver, ISO, and other styles
47

Lumbantobing, Romauli, Rani Sauriasari, and Retnosari Andrajati. "ROLE OF PHARMACISTS IN REDUCING DRUG-RELATED PROBLEMS IN HEMODIALYSIS OUTPATIENTS." Asian Journal of Pharmaceutical and Clinical Research 10, no. 17 (October 1, 2017): 108. http://dx.doi.org/10.22159/ajpcr.2017.v10s5.23110.

Full text
Abstract:
Objectives: Hemodialysis outpatients have a higher risk of developing drug-related problems. Pharmacists play a key role in identifying and preventing these drug-related problems. This study aimed to assess the effect of pharmacist intervention on the number and types of drug-related problems in outpatients undergoing hemodialysis at Indonesia Christian University Hospital.Methods: This pre- and post-prospective study was conducted from January 2013 to June 2013. We evaluated 86 patients who were prescribed 804 drugs.Results: A total of 337 drug-related problems were identified (41.86% of the total drugs prescribed). The types of drug-related problems identified were as follows: Failed therapy (18.69%); sub-optimal therapy (52.23%); indication of non-administration of therapy (2.37%); and non-allergic adverse drug effects (26.71%). The physicians received 59 recommendations, and the patients received 278 recommendations. These recommendations resulted in a decrease in ineffective drug therapy or therapeutic failure (18.69-0%), sub-optimal therapy (52.23-21.36%), indications of non-administration of drug (2.37-2.08%), and non-allergic adverse drug effects (26.71-9.20%). The factors that significantly affected the occurrence of drug-related problems were hemodialysis frequency, number of comorbidities, and number of drugs prescribed. Patients undergoing hemodialysis 3 times a week were more likely to experience a decrease in drug-related problems than those undergoing hemodialysis twice a week (odds ratio 26.33, 95% confidence interval 2.710-255.884).Conclusions: Pharmacist intervention could decrease drug-related problems in hemodialysis patients.
APA, Harvard, Vancouver, ISO, and other styles
48

Shukil, L. V., L. V. Moshkova, and E. A. Korzhavych. "THE PROBLEMS OF BENEFICIAL DRUG SUPPORT." Pharmacy & Pharmacology 3, no. 3(10) (September 17, 2015): 33. http://dx.doi.org/10.19163/2307-9266-2015-3-3(10)-33-39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

van den Bemt, Patricia M. L. A., Toine C. G. Egberts, Lolkje T. W. de Jong-van den Berg, and Jacobus R. B. J. Brouwers. "Drug-Related Problems in Hospitalised Patients." Drug Safety 22, no. 4 (2000): 321–33. http://dx.doi.org/10.2165/00002018-200022040-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Meyboom, Ronald H., Marie Lindquist, and Antoine C. Egberts. "An ABC of Drug-Related Problems." Drug Safety 22, no. 6 (2000): 415–23. http://dx.doi.org/10.2165/00002018-200022060-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Drug problems' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography